Botulinum toxin A for the treatment of strabismus in children with neurological impairment / Toxına botulínica tipo A para o tratamento de estrabısmo em crianças neurologicamente comprometidas

ABSTRACT Purposes: To assess the efficacy of botulinum toxin A injection in the treatment of strabismus in patients with neurological impairment and evaluate the factors associated with treatment success. Methods: The study included 50 patients with strabismus and neurological impairment. In all children, botulinum toxin injection was performed into the appropriate extraocular muscle. The relationship between demographic features, clinical characteristics, and treatment success were analyzed. Results: In the study group, 34 patients had esotropia, and 16 patients had exotropia. As neurological problems, 36 patients had cerebral palsy, and 14 had hydrocephalus. The average follow-up period was 15.3 ± 7.3 months. The mean number of injections was 1.4 ± 0.6. The mean angle of deviation was 42.5 ± 13.2 PD before the treatment, which decreased to 12.8 ± 11.9 PD after the treatment. Successful motor alignment (orthotropia within 10 PD) was achieved in 60% of the patients. Binary logistic regression analysis revealed that esotropic misalignment and shorter duration of strabismus was significantly associated with treatment success in the study group. Patients with esotropia and lower angles of misalignment were more likely to be treated with a single injection. Conclusion: The use of botulinum toxin A for the treatment of strabismus in children with neurological impairment is a good alternative to conventional surgical therapy with a lower risk of overcorrection. The treatment outcome is better in esodeviations and shorter duration of strabismus, implying an advantage of early treatment.

RESUMO Objetivos: Avaliar a eficácia do uso de toxina bo-tulínica tipo A no tratamento do estrabismo em pacientes com comprometimento neurológico e avaliar os fatores associados ao sucesso do tratamento. Métodos: Cinquenta pacientes com estrabismo e comprometimento neurológico foram incluídos no estudo. Em todas as crianças, a toxina botulínica tipo A foi injetada no músculo extraocular apropriado. A relação entre características demográficas, características clínicas e o sucesso do tratamento foram analisadas. Resultados: No grupo de estudo, 34 pacientes tiveram esotropia e 16 pacientes tiveram exotropia, sendo trinta e seis pacientes com paralisia cerebral e 14 pacientes com hidrocefalia. O tempo médio de acompanhamento foi de 15,3 ± 7,3 meses. O número médio de aplicações foi de 1,4 ± 0,6. O ângulo de desvio médio foi de 42,5 ± 13,2 DP antes do tratamento e diminuiu para 12,8 ± 11,9 DP após o tratamento. Alinhamento motor bem sucedido (ortotropia dentro de 10 DP) foi alcançado em 60% dos pacientes. A análise de regressão logística binária revelou que o desalinhamento esotrópico e uma menor duração do estrabismo foram significativamente associados ao sucesso do tratamento no grupo de estudo. Pacientes esotrópicos com ângulos de desalinhamento menores são mais propensos a serem tratados com uma única aplicação. Conclusão: O uso da toxina botulínica tipo A para o tratamento de estrabismo em crianças com comprometimento neurológico é uma boa alternativa para a terapia cirúrgica convencional com menor risco de hipercorreção. O resultado do tratamento é melhor em exodesvios e em pacientes com estrabismo de menor duração, implicando em vantagem para o tratamento precoce.

The state of the art in therapeutic administration of botulinum toxin in children with cerebral palsy: an integrative review / O estado da arte em aplicação terapêutica de toxina botulínica em crianças com paralisia cerebral: uma revisão integrativa

ABSTRACT Objective: To describe the current state of the art in the therapeutic administration of botulinum toxin with indications, efficacy, and safety profile for children and adolescents with cerebral palsy. Data source: An integrative review was conducted. The MEDLINE/PubMed database was searched twice within the last decade using distinct terms, and only studies written in the English language were included. The study population was limited to those aged 0-18 years. Articles that were duplicates or lacked sufficient methodology information were excluded. Data synthesis: We found 256 articles, of which 105 were included. Among the included studies, most were conducted in developed countries. Botulinum toxin demonstrated good safety and efficacy in reducing spasticity, particularly when administered by a multidisciplinary rehabilitation team. It is primarily utilized to improve gait and upper limb function, facilitate hygiene care, reduce pain, prevent musculoskeletal deformities, and even decrease sialorrhea in patients without a functional prognosis for walking. Conclusions: The administration of botulinum toxin is safe and efficacious, especially when combined with a multi-professional rehabilitation team approach, which increases the probability of functional improvement. It can also be beneficial for patients with significant functional impairments to help with daily care tasks, such as hygiene, dressing, and reducing sialorrhea. Pediatricians must be familiar with this treatment and its indications to attend to and refer patients promptly when necessary, and to exploit their neuroplasticity. Further research on this topic is required in developing countries.

RESUMO Objetivo: Descrever o estado da arte em aplicação terapêutica de toxina botulínica com indicações, eficácia e perfil de segurança em crianças e adolescentes com paralisia cerebral. Fontes de dados: Realizada revisão integrativa através de busca na base de dados MEDLINE/PubMed em dois momentos nos últimos 10 anos, e termos distintos, em inglês, numa população entre 0 e 18 anos de idade. Excluiu-se artigos duplicados ou com informações insuficientes de metodologia. Síntese dos dados: 256 artigos foram encontrados e 105 foram incluídos, sendo a maior parte realizados em países desenvolvidos. A toxina botulínica mostrou boa segurança e efetividade na redução da espasticidade, especialmente administrada por uma equipe de reabilitação multiprofissional, usada principalmente para: melhora da marcha e da função dos membros superiores, facilitação dos cuidados de higiene, analgesia e prevenção de deformidades musculoesqueléticas, além de redução da sialorreia, inclusive em pacientes sem prognóstico funcional de marcha. Conclusões: A aplicação de toxina botulínica foi efetiva e segura, principalmente quando atrelada a uma abordagem por equipe de reabilitação multiprofissional, o que aumenta as chances de melhora funcional. Mostrou-se benéfica também para pacientes com grandes comprometimentos funcionais para facilitar os seus cuidados diários em relação à higiene, colocar e tirar roupas e redução da sialorreia. O pediatra deve estar familiarizado com esse tratamento e suas indicações para atender e direcionar pacientes o mais breve possível quando indicado e aproveitar o máximo de neuroplasticidade. Há necessidade de investimentos em mais pesquisas sobre este tema em países em desenvolvimento.

Manejo exitoso de síndrome de vejiga hiperactiva refractaria con toxina botulínica A / Successful management of refractory overactive bladder syndrome with botulinum toxin A

Introducción: El síndrome de vejiga hiperactiva (VHA) afecta hasta al 43% de las mujeres. La terapia escalonada incluye cambios de hábitos, fármacos y neuromodulación. Hasta el 40% de las pacientes llegan a requerir terapia avanzada alternativa, como toxina botulínica (TB). Objetivo: Reportar los resultados del tratamiento con toxina botulínica en mujeres con VHA refractaria a tratamiento de primera y segunda línea, en un hospital público en Chile. Método: Estudio de cohorte retrospectivo desde una base de datos recolectada prospectivamente del Hospital Sótero del Río entre 2018 y 2022. Se incluyeron 33 pacientes con tratamiento farmacológico y neuromodulación previa, con una edad promedio de 57 años, sometidas a inyección cistoscópica de TB a detrusor, analizando datos demográficos, antecedentes y complicaciones. Se realizó seguimiento con frecuencia miccional, paños/día, escala de gravedad de Sandvik (ISI) y encuesta Patient Global Impression Improvement (PGI-I). Resultados: Los datos comparativos pre/post TB, respectivamente, fueron: frecuencia miccional diurna 11/6 y nocturna 5/1; paños/día 5/3; ISI 8/3. Veinte de 33 mujeres refirieron estar excelente o mucho mejor (PGI-I). Conclusiones: Es posible realizar manejo con TB en mujeres con VHA refractaria a primera y segunda línea, con buenos resultados e impacto significativo en la calidad de vida.

Introduction: Overactive bladder syndrome (OABS) affects up to 43% of women. Staggered therapy includes habit changes, drugs, and peripheral neuromodulation. Up to 40% of patients may require advanced alternative therapy such as botulinum toxin A (BT). Objective: To report the results of treatment with TB in women with OABS refractory to first- and second-line treatment in a public hospital in Chile. Method: Retrospective cohort study from prospectively collected database from Hospital Sótero del Río between 2018 and 2022. Thirty-three patients with previous pharmacological treatment and neuromodulation were included, with an average age of 57 years, undergoing cystoscopic injection of TB to detrusor. Demographic data, history, and complications were analyzed. Follow-up was performed with voiding frequency, cloths/day, Sandvik Severity Scale (ISI) and Patient Global Impression Improvement (PGI-I) survey. Results: Comparative data pre/post TB, respectively showed: daytime voiding frequency 11/6 and nighttime 5/1; cloths/day 5/3; ISI 8/3. 20 of 33 women reported being excellent or much better (PGI-I). Conclusions: TB management in women with OABS refractory to first- and second-line treatment has good results and significant impact on quality of life.

Cirugía de desfuncionalización de glándulas salivales mayores en sialorrea masiva / Major salivary gland defunctionalization surgery in massive sialorrhea

Introducción: La sialorrea es la pérdida involuntaria de saliva de la boca, ya sea debido a la producción excesiva de saliva o disminución de la frecuencia de deglución. Se habla de sialorrea patológica cuando persiste más allá de los 4 años de edad. Además de las implicaciones sociales, cambios de ropa frecuentes, puede provocar neumonías por aspiración y deshidratación. El manejo de la sialorrea requiere una evaluación completa con un enfoque de equipo multidisciplinario para el tratamiento, que incluye terapias no farmacológicas, farmacológicas y quirúrgicas. Objetivo: Presentar resultados quirúrgicos y farmacológicos en el tratamiento de sialorrea masiva. Material y Método: Se realizó revisión de historias clínicas de 7 pacientes portadores de sialorrea masiva. Todos los pacientes incluidos fueron refractarios a tratamiento médico. El diagnóstico fue obtenido por un equipo multidisciplinario. Se les realizó desfuncionalización quirúrgica y farmacológica de glándulas salivales. Se les aplicó Escala de Severidad (DSS) y escala de frecuencia (DFS), previo a cirugía y posterior a procedimiento hasta el año. Resultados: Mejoría clínica subjetiva posterior a desfuncionalización quirúrgica con disminución de DSS y DFS. Disminución promedio de baberos a 10/día. Conclusión: Los resultados obtenidos son buenos, si se consideran las escalas DSS, DFS y el número de baberos al día, que son mediciones tanto subjetivas y objetivas respectivamente.

Introduction: Massive Sialorrhea is the involuntary loss of saliva from the mouth, either due to excessive saliva production or decreased swallowing frequency. We speak of pathological sialorrhea when it persists beyond 4 years old. In addition to the social implications and frequent clothing changes. It can cause aspiration pneumonia and dehydration. Treatment for sialorrhea requires a comprehensive evaluation with a multidisciplinary team approach. Including non-pharmacological, pharmacological, and surgical therapies. Aim: Presentation of the results of surgical defunctionalization of the salivary glands plus injection of Botulinum Toxin in the treatment of massive sialorrhea. Material and Method: A review of the clinical records of 7 patients with massive sialorrhea was carried out. All included patients were refractory to medical treatment. The diagnosis was obtained by a multidisciplinary team. Surgical and pharmacological dysfunctionalization of salivary glands was performed. Severity Scale (DSS) and Frequency Scale (DFS) were applied before surgery and after the procedure up to a year. Results: Subjective clinical improvement after surgical defunctionalization with decreased SHD and DFS. Average decrease in bibs to 10/day. Conclusion: The evaluated strategy presented similar benefits with respect to the literature. The SHD and DFS scales and the number of bibs per day are both subjective and objective measurements, respectively, and allow the clinical improvement and quality of life of patients undergoing surgery to be evaluated individually.

Cierre dinámico y toxina botulínica: una alternativa novedosa para el cierre definitivo del abdomen abierto y contenido / Dynamic closure system and botulinum toxin: a novel alternative for definitive closure of open abdomen

RESUMEN Se presenta el caso de un paciente masculino de 54 años que, cursando internación por neumonía- COVID-19, intercurrió con shock séptico por diverticulitis aguda Hinchey IV, por lo que se realizó cirugía de Hartmann. Evolucionó con isquemia colónica, se realizó colectomía total y abdomen abierto y contenido (AAyC). El manejo del AAyC se realizó con sistema de vacío (VAC) durante 7 semanas, resultando un AAyC tipo IIIa (Björck) con un gap de 16 cm. Se decidió iniciar, una vez dadas las condiciones clínicas del paciente, el cierre dinámico (CD) con tracción fascial con malla de polipropileno asociado a inyección de toxina botulínica (TB). Esta estrategia permitió el cierre fascial primario (CFP) de la pared abdominal en la quinta semana de comenzado el tratamiento, evitando de esta manera la morbilidad de un cierre por segunda intención.

ABSTRACT We report the case of a 54-year-old male patient hospitalized for COVID-19 pneumonia who developed septic shock due to acute Hinchey IV diverticulitis and required Hartmann's surgery. The patient evolved with colonic ischemia and underwent total colectomy and open abdomen (OA) with temporary abdominal closure (TAC) that was managed with a vacuum-assisted wound closure (VAWC) system for 7 weeks, resulting in a Björck grade 3A OA with a 16-cm gap. As he had a favorable clinic course, dynamic closure with mesh-mediated fascial traction was decided, associated with botulinum toxin (BT) injection. This strategy allowed primary fascial closure (PFC) of the abdominal wall 5 weeks after treatment was initiated, thus avoiding the complications of healing by secondary intention.

Protective Effect of Qihong Tongluo Prescription on Vascular Endothelial Cells in Rats with Deep Venous Thrombosis Based on NF-κB Pathway / 中国实验方剂学杂志

ObjectiveTo explore the protective effect and mechanism of Qihong Tongluo prescription on vascular endothelial cells in rats with deep venous thrombosis （DVT）. MethodSixty-six SD rats were randomly divided into a blank group （n=11） and a modeling group （n=55）. The DVT model was induced in rats of the modeling group by slowing down blood flow and damaging vascular endothelium. The model rats were randomly divided into model group， aspirin group （200 mg·kg-1）， and low-，medium-， and high-dose Qihong Tongluo prescription groups （6.5， 13， 26 g·kg-1） according to a random number table. Rats were treated with corresponding drugs by gavage， while those in the model group and the blank group received normal saline， once per day for 7 days. The rats were sacrificed and the abdominal aortic blood was taken. The levels of serum endothelin-1 （ET-1） and interleukin-6 （IL-6） were detected by enzyme-linked immunosorbent assay （ELISA）. Hematoxylin-eosin （HE） staining was used to observe the pathological changes in vascular endothelial tissues. The ultrastructure of vascular endothelial cells was observed by the transmission electron microscope. The viability of vascular endothelial cells was detected by methylthiazolyldiphenyl-tetrazolium bromide （MTT） method，and the release level of lactate dehydrogenase （LDH） was detected by the LDH kit. The messenger ribonucleic acid （mRNA） expression of platelet-activating factor （PAF），nuclear transcription factor κB （NF-κB），Ras-related C3 botulinum toxin substrate 1 （Rac1）， and Ras-related C3 botulinum toxin substrate 2 （Rac2） in vascular endothelial tissues were detected by real-time reverse transcription polymerase chain reaction （Real-time PCR）. The protein expression of PAF，NF-κB，Rac1， and Rac2 in vascular endothelial tissues was detected by Western blot. ResultThe model group showed seriously damaged and swollen vascular endothelial cells with massive shedding， attachment of massive inflammatory cells， nucleus pyknosis and deformation under the electron microscope， highly swollen mitochondria， serious cytoplasmic vacuolation，and exposure of internal elastic membrane. The damage of vascular endothelium and its ultrastructure in Qihong Tongluo prescription groups and the aspirin group was improved in varying degrees. Compared with the blank group，the model group showed increased levels of serum ET-1 and IL-6，potentiated vascular endothelial cell viability， up-regulated mRNA and protein expression of PAF，NF-κB，Rac1， and Rac2 in vascular endothelial tissues，and decreased LDH release level of vascular endothelial cells （P<0.05）. Compared with the model group，the aspirin group and the Qihong Tongluo prescription groups showed decreased levels of serum ET-1 and IL-6，blunted vascular endothelial cell viability，down-regulated mRNA and protein expression of PAF，NF-κB，Rac1， and Rac2 in vascular endothelial tissues，and increased LDH release level of vascular endothelial cells （P<0.05）. The effect of Qihong Tongluo prescription was dose-dependent. ConclusionQihong Tongluo prescription has a protective effect on vascular endothelial cells of DVT rats and can prevent and treat thrombosis，and its therapeutic effect is presumably achieved by inhibiting the expression of PAF，NF-κB，Rac1，and Rac2 and reducing the levels of serum ET-1 and IL-6.

Síndrome de arlequim idiopática: sucesso terapêutico com toxina botulínica / Idiopathic harlequin syndrome: successful therapy with botulium toxin

A síndrome de arlequim é uma rara desordem autonômica que se caracteriza por anidrose e falta de rubor unilateral da face, podendo acometer as regiões cervical e torácica. De forma paradoxal, há rubor e sudorese compensatórios no lado contralateral à alteração. É idiopática na maioria dos casos, mas pode ser congênita, secundária a lesões estruturais e à iatrogenia pós-cirúrgica. O tratamento é direcionado ao fator causal. Descreve-se caso de paciente com diagnóstico de síndrome de arlequim idiopática, sendo realizada aplicação de toxina botulínica na hemiface acometida pelos sintomas compensatórios com boa resposta terapêutica

Harlequin syndrome is a rare autonomic disorder characterized by anhidrosis and lack of unilateral flushing of the face, which may affect the cervical and thoracic regions. Paradoxically, there is compensatory flushing and sweating on the contralateral side to the alteration. It is idiopathic in most cases, but it can be congenital or secondary to structural or post-surgical iatrogenic lesions. Treatment is directed at the causative factor. We describe the case of a patient with a diagnosis of idiopathic Harlequin Syndrome with botulinum toxin application in the hemiface affected by compensatory symptoms with good therapeutic response.

Efeito prolongado da toxina botulínica associada à suplementação com zinco e fitase / Prolonged effect of botulinum toxin associated with zinc and phytase supplementation / Efecto prolongado de la toxina de botulino asociada con el suplemento de zinc y la fitasa

A toxina botulínica é produzida naturalmente pela bactéria anaeróbia gram- positiva Clostridium botulinum, sendo considerada uma neurotoxina com efeitos capazes de reduzir atividades do sistema nervoso parassimpático, principalmente em relação as desordens de movimentos. A alta efetividade e o resultado do efeito de bloqueio na contração da musculatura facial justificam sua aplicação regular na estética, atuando no tratamento e prevenção das rugas e linhas de expressão. Entretanto, para a ação da toxina botulínica é necessário que o Zinco (Zn) exerça a ação no bloqueio da contração muscular através do mecanismo da clivagem no receptor SNAP-25. O objetivo deste trabalho é investigar a correlação do mecanismo de ação da toxina botulínica no bloqueio da contração muscular associado com a suplementação via oral de cápsulas de zinco e fitase, para comprovar a efetividade na durabilidade de bloqueio muscular com TBA. A pesquisa foi realizada através da aplicação de um questionário aleatório para participantes da pesquisa que fazem aplicação de TBA na musculatura facial de ambos os gêneros, com idade acima de 18 anos e que realizam a suplementação prévia de Zn e Fitase para aumentar a durabilidade do efeito da neurotoxina. Em relação aos resultados encontrados observou-se uma mudança significativa na duração do efeito da TBA quando associado a suplementação prévia de Zn e fitase. Dos 44 participantes da pesquisa 22,7% responderam que ficaram satisfeitos com os efeitos da TBA sem suplementação prévia, enquanto 93,2% afirmaram no questionário uma duração maior do bloqueio muscular quando suplementaram previamente com Zn e Fitase. Conclui-se que a suplementação de Zn e fitase previamente a aplicação da TBA tem resultado positivo na durabilidade do bloqueio da contração da musculatura facial, o que desperta grande interesse na área da estética aplicada, sugerindo novas terapias complementares que possam assegurar a satisfação dos pacientes que são adeptos a este procedimento estético.

Botulinum toxin is produced naturally by the anaerobic gram-positive bacterium Clostridium botulinum, being considered a neurotoxin with effects capable of reducing activities of the parasympathetic nervous system, mainly in relation to movement disorders. The high effectiveness and the result of the blocking effect in the contraction of the facial musculature justify its regular application in aesthetics, acting in the treatment and prevention of wrinkles and lines of expression. However, for the action of botulinum toxin it is necessary that Zinc (Zn) exerts the action in blocking muscle contraction through the cleavage mechanism in the SNAP-25 receptor. The objective of this work is to investigate the correlation of the mechanism of action of botulinum toxin in the blocking of muscle contraction associated with oral supplementation of zinc capsules and phytase, to prove the effectiveness in the durability of muscle block with TBA.The research was carried out by applying a random questionnaire to research participants who apply TBA in the facial musculature of both genders, aged over 18 years and who perform the previous Zn and Fitase supplementation to increase the durability of the effect of neurotoxin. In relation to the results found, a significant change in the duration of the effect of TBA was observed when associated with previous Zn and phytase supplementation. Of the 44 participants in the survey, 22.7% responded that they were satisfied with the effects of ABR without prior supplementation, while 93.2% stated in the questionnaire a longer duration of muscle block when they had previously supplemented with Zn and Fitase. It is concluded that the Zn and phytase supplementation prior to the application of the TBA has positive result in the durability of the blockage of the contraction of the facial musculature, which arouses great interest in the area of applied aesthetics, suggesting new complementary therapies that can ensure the satisfaction of patients who are adherents to this aesthetic procedure.

La toxina botulínica es producida naturalmente por la bacteria anaeróbica Gram-positiva Clostridium botulinum y se considera una neurotoxina con efectos capaces de reducir las actividades del sistema nervioso parasiinfático, principalmente en relación con los trastornos del movimiento. La alta eficacia y el resultado del efecto bloqueante sobre la contracción de los músculos faciales justifican su aplicación regular en estética, actuando en el tratamiento y prevención de arrugas y líneas de expresión. Mientras tanto, para la acción de la toxina botulínica, es necesario que Zinc (Zn) ejerza la acción de bloqueo de la contracción muscular por el mecanismo de escisión del receptor SNAP-25. El objetivo de este trabajo es investigar la correlación del mecanismo de acción de la toxina botulínica en el bloqueo de la contracción muscular asociada a la suplementación oral de cápsulas de zinc y fitasa, para probar la eficacia de la durabilidad del bloqueo muscular con TBA. La investigación se realizó aplicando un cuestionario aleatorio a los participantes en la investigación que aplican TBA a los músculos faciales de ambos géneros mayores de 18 años y que realizan el suplemento previo de Zn y Fitase para aumentar la durabilidad del efecto neurotoxina. En relación con los resultados hallados, se observó un cambio significativo en la duración del efecto del TBA cuando se asoció con el suplemento de Zn y fitasa. De los 44 participantes en la investigación, el 22,7% respondió que estaban satisfechos con los efectos de la TBA sin suplementos previos, mientras que el 93,2% declaró en el cuestionario una larga duración del bloqueo muscular cuando se les había suplementado previamente con Zn y Fitase. Se concluye que la suplementación con Zn y fitasa previa a la aplicación del TBA ha producido un resultado positivo en la durabilidad del bloqueo de contracción muscular facial, que despierta gran interés en el área de estética aplicada, sugiriendo nuevas terapias complementarias que puedan garantizar la satisfacción de los pacientes que son adeptivos a este procedimiento estético.

Efeito prolongado da toxina botulínica associada à suplementação com zinco e fitase / Prolonged effect of botulinum toxin associated with zinc and phytase supplementation / Efecto prolongado de la toxina de botulino asociada con el suplemento de zinc y la fitasa

A toxina botulínica é produzida naturalmente pela bactéria anaeróbia gram- positiva Clostridium botulinum, sendo considerada uma neurotoxina com efeitos capazes de reduzir atividades do sistema nervoso parassimpático, principalmente em relação as desordens de movimentos. A alta efetividade e o resultado do efeito de bloqueio na contração da musculatura facial justificam sua aplicação regular na estética, atuando no tratamento e prevenção das rugas e linhas de expressão. Entretanto, para a ação da toxina botulínica é necessário que o Zinco (Zn) exerça a ação no bloqueio da contração muscular através do mecanismo da clivagem no receptor SNAP-25. O objetivo deste trabalho é investigar a correlação do mecanismo de ação da toxina botulínica no bloqueio da contração muscular associado com a suplementação via oral de cápsulas de zinco e fitase, para comprovar a efetividade na durabilidade de bloqueio muscular com TBA. A pesquisa foi realizada através da aplicação de um questionário aleatório para participantes da pesquisa que fazem aplicação de TBA na musculatura facial de ambos os gêneros, com idade acima de 18 anos e que realizam a suplementação prévia de Zn e Fitase para aumentar a durabilidade do efeito da neurotoxina. Em relação aos resultados encontrados observou-se uma mudança significativa na duração do efeito da TBA quando associado a suplementação prévia de Zn e fitase. Dos 44 participantes da pesquisa 22,7% responderam que ficaram satisfeitos com os efeitos da TBA sem suplementação prévia, enquanto 93,2% afirmaram no questionário uma duração maior do bloqueio muscular quando suplementaram previamente com Zn e Fitase. Conclui-se que a suplementação de Zn e fitase previamente a aplicação da TBA tem resultado positivo na durabilidade do bloqueio da contração da musculatura facial, o que desperta grande interesse na área da estética aplicada, sugerindo novas terapias complementares que possam assegurar a satisfação dos pacientes que são adeptos a este procedimento estético.

Botulinum toxin is produced naturally by the gram-positive anaerobic bacterium Clostridium botulinum, and is considered a neurotoxin with effects capable of reducing activities of the parasympathetic nervous system, especially in relation to movement disorders. The high effectiveness and the result of the blocking effect on the contraction of facial muscles justify its regular application in aesthetics, acting in the treatment and prevention of wrinkles and expression lines. However, for the action of botulinum toxin it is necessary that the Zinc (Zn) exerts the action of blocking muscle contraction through the cleavage mechanism in the SNAP-25 receptor. The objective of this study is to investigate the correlation of the mechanism of action of botulinum toxin in blocking muscle contraction associated with oral supplementation of zinc capsules and phytase, to prove the effectiveness in the durability of muscle blockade with TBA. The research was carried out by applying a randomized questionnaire to research participants who apply TBA to the facial muscles of both genders, over 18 years of age, and who perform prior supplementation of Zn and Phytase to increase the durability of the neurotoxin effect. In relation to the results found it was observed a significant change in the duration of the effect of TBA when associated with prior supplementation of Zn and phytase. Of the 44 research participants 22.7% responded that they were satisfied with the effects of TBA without prior supplementation, while 93.2% stated in the questionnaire a longer duration of muscle blockade when previously supplemented with Zn and Phytase. We conclude that the supplementation of Zn and phytase previously to the application of TBA has a positive result in the durability of the blockade of facial muscle contraction, which arouses great interest in the area of applied esthetics, suggesting new complementary therapies that can ensure the satisfaction of patients who are adept at this esthetic procedure.

La toxina botulínica es producida naturalmente por la bacteria anaeróbica Gram-positiva Clostridium botulinum y se considera una neurotoxina con efectos capaces de reducir las actividades del sistema nervioso parasiinfático, principalmente en relación con los trastornos del movimiento. La alta eficacia y el resultado del efecto bloqueante sobre la contracción de los músculos faciales justifican su aplicación regular en estética, actuando en el tratamiento y prevención de arrugas y líneas de expresión. Mientras tanto, para la acción de la toxina botulínica, es necesario que Zinc (Zn) ejerza la acción de bloqueo de la contracción muscular por el mecanismo de escisión del receptor SNAP-25. El objetivo de este trabajo es investigar la correlación del mecanismo de acción de la toxina botulínica en el bloqueo de la contracción muscular asociada a la suplementación oral de cápsulas de zinc y fitasa, para probar la eficacia de la durabilidad del bloqueo muscular con TBA. La investigación se realizó aplicando un cuestionario aleatorio a los participantes en la investigación que aplican TBA a los músculos faciales de ambos géneros mayores de 18 años y que realizan el suplemento previo de Zn y Fitase para aumentar la durabilidad del efecto neurotoxina. En relación con los resultados hallados, se observó un cambio significativo en la duración del efecto del TBA cuando se asoció con el suplemento de Zn y fitasa. De los 44 participantes en la investigación, el 22,7% respondió que estaban satisfechos con los efectos de la TBA sin suplementos previos, mientras que el 93,2% declaró en el cuestionario una larga duración del bloqueo muscular cuando se les había suplementado previamente con Zn y Fitase. Se concluye que la suplementación con Zn y fitasa previa a la aplicación del TBA ha producido un resultado positivo en la durabilidad del bloqueo de contracción muscular facial, que despierta gran interés en el área de estética aplicada, sugiriendo nuevas terapias complementarias que puedan garantizar la satisfacción de los pacientes que son adeptivos a este procedimiento estético.

Clinical application of botulinum toxin type A in the treatment of thyroid-associated ophthalmopathy / 国际眼科杂志(Guoji Yanke Zazhi)

Thyroid-associated ophthalmopathy(TAO)is an autoimmune inflammatory disease involving multiple orbital tissues with a variety of clinical manifestations, which has serious effects on the life quality of patients.Interventions of TAO mainly include medical treatment to stabilize thyroid function, reduce inflammation and regulate immune function, as well as surgical treatment to relieve ocular symptoms. Botulinum toxin type A can paralyze muscles by blocking nerve impulse conduction at the neuromuscular junction, which is of certain therapeutic value for restrictive strabismus due to extraocular muscle involvement and upper eyelid retraction due to involvements of levator palpebrae superioris and Müller's muscle in TAO patients, especially when they have surgical contraindications, lack surgical opportunity, or refuse surgery. This paper reviews the application of botulinum toxin type A in the treatment of TAO, focusing on its pharmacological mechanism, dosage, effectiveness, and possible complications when treating restrictive strabismus and upper eyelid retraction, and discussing potential therapeutic values of botulinum toxin type A for intraocular pressure elevation, glabellar frown lines and dry eye caused by extraocular muscle compression in TAO patients, in order to provide a reference for clinical intervention.

Clinical efficacy of botulinum toxin A in the treatment of hand hyperhidrosis / 中华医学美学美容杂志

Objective:To investigate the clinical efficacy of botulinum toxin A in the treatment of hand hyperhidrosis.Methods:One hundred patients with hand hyperhidrosis were treated with botulinum toxin A (BTXA, Lanzhou Biotechnology Development Co., Ltd., Botulinum Toxin Type A for Injection Hengli) injection, a total of 200 U. Each hand was injected with 100 U respectively. The curative effect was evaluated by self-made questionnaire. The scores of the two were added. The subjective and objective evaluation were carried out before and after injection, and the patients were rechecked 2 weeks, and 1, 4 and 6 months after injection. Efficacy, patient satisfaction and adverse reactions were evaluated.Results:Compared with before treatment, the effective rate increased 2 weeks after injection, 1 month after injection, 4 months after injection and 6 months after injection, and the difference was statistically significant (Chi-square value was 31.54, 36.33, 28.34, 25.23, respectively, P<0.05). After 6 months of follow-up, the effect gradually decreased, and the curative effect could be maintained for about 10 months. After recurrence, the symptoms of hand sweating were still reduced. Satisfaction 96%; Adverse reactions were mild, subcutaneous blood stasis, 27% hand muscles were slightly weak, and returned to normal after 2-3 weeks. Conclusions:Botulinum toxin A injection has certain curative effect, high safety and less adverse reactions. It is an ideal method for the treatment of hand hyperhidrosis.

Effect of botulinum toxin type A on children with odorihidrosis / 中华医学美学美容杂志

Objective:To investigate the effect of botulinum toxin type A on children with odorihidrosis.Methods:From March 2017 to February 2021, 121 children with odorihidrosis, including 48 males and 73 females, aged 13 to 17 (15.9±1.2) years, were admitted to the Burn and Plastic Surgery Department of the 980 Hospital of PLA. There were 24 cases in mild group, 50 cases in moderate group and 47 cases in severe group. Botulinum toxin A was injected into 20-50 points on each side, and 1 U was injected into each point. The total amount of botulinum toxin A was 50-100 U on both sides.Results:Three groups of children were evaluated for efficacy, 24 cases of mild group was significantly effective in 23 cases, accounting for 95.8%. In the moderate group, 46 (92.0%) of 50 cases showed obvious effect. 49 cases (98.0%) were effective; In the severe group, 40 cases (85.1%) showed obvious effect and 45 cases (95.7%) were effective. Three groups of children with different efficacy had no statistical significance ( P>0.05). The significant efficiency in mild and moderate groups was higher than that in severe group, and the difference was statistically significant ( P<0.05). Conclusions:Botulinum toxin type A is effective in the treatment of children with mild and moderate bromhidrosis, and is worthy of clinical application.

Supplementing rehabilitation training with botulinum neurotoxin improves outcomes for Parkinson′s disease patients with striatal foot deformity / 中华物理医学与康复杂志

Objective:To observe any therapeutic effect of combining botulinum toxin type A (BTX-A) with rehabilitation training in treating Parkinson′s disease (PD) patients with striatal foot deformity (SFD).Methods:A total of 68 PD patients with SFD were randomly divided into a control group and a treatment group. Both groups were given routine medication with pramipexole and dopamine receptor agonists and received lower limb rehabilitation training, including passive activity training, strength training and walking training. The treatment group was additionally injected with BTX-A. Sciatic pain was quantified using a visual analogue scale. The Unified Parkinson′s Disease Rating Scale-lower limb motor lower limb motor function (UPDRS-LLM) scale, the Berg balance scale and the modified Barthel index were applied to test all of the participants before the experiment and on the 7th, 14th and 30th day of the treatment.Results:The average scores of the control group on all of measures at were significantly better than those of the control group at the same time points, and by the 14th and 30th day had improved significantly compared with those before treatment.Conclusion:Supplementing rehabilitation training with BTX-A can significantly improve foot deformity and relieve the muscle tension and spastic pain of PD patients with SFD, promoting the motor functioning of their lower limbs, their balance and their performance in the activities of daily living.

Prospective study of the aesthetic effect of botulinum toxin a when injected into the muscles of facial expression

Botulinum neurotoxin A (BoNT-A) causes an anticholinergic effect on neuronal fibers, which control muscle contraction and autonomic disorders. Thus, it has been widely used in facial aesthetics, decreasing the action of motor muscles and consequent wrinkles. This preliminary study evaluated the effect of BoNT-A in 77 patients, the treatment satisfaction index was defined in percentage (from 0% to 100%). The evaluation was carried out on 15th, 30th, 60th, 90th, and 180th days after BoNT. The data were analyzed using the Friedman, Student t, Mann-Whitney test with t (alpha=0.05). The results showed that at 15th and 30th days the scores were similar in all muscles with high level of satisfaction and until 90th days the scores decreased significantly for Corrugator supercilii 79.38%, Occipitofrontalis 71.46%, Orbicularis oculi 70.43%; but the satisfaction was good. At 180 days, there was a drop in effectiveness in all treated muscles since the scores decreased significantly, showing low satisfaction by the participants. This study demonstrated that the BoNT-A had attested satisfaction effect by participants for up to 90th days, but at 180th days the satisfaction was low. In the comparative analyzes between women under 40 and over 40 years of age, there was no significant differences.

Uso da toxina botulínica tipo A no tratamento da espasticidade em crianças com paralisia cerebral: revisão sistemática / Use of botulinum toxin type A in the treatment of spasticity in children with cerebral palsy: systematic review

Há pouco mais de duas décadas, a toxina botulínica tipo A (TBA) vem sendo utilizada como parte do tratamento multimodal para a redução do tônus muscular em crianças com paralisia cerebral (PC) espástica. Objetivos: determinar a eficácia e segurança, avaliar as doses utilizadas em cada faixa etária e comparar os custos entre as TBA's para tratamento da espasticidade em crianças portadoras de PC. Métodos: foi realizada uma revisão sistemática de estudos publicados nos últimos 6 anos, de 2017 a abril de 2022, através das bases de dados do PubMed, SciELO, Science Direct, Google Acadêmico e Periódicos CAPES, de acordo com os seguintes critérios de inclusão: (1) termos de busca: toxina botulínica, espasticidade e paralisia cerebral; (2) idioma: português, inglês e espanhol; (3) desenho: ensaios clínicos randomizados e duplo-cego, revisões sistemáticas e metanálises; (4) população: crianças e adolescentes com PC espástica; (5) intervenção: TBA; (6) grupo controle com outro tratamento para PC ou sem intervenção; (7) desfecho: alteração na Escala de Ashworth Modificada, efeitos adversos e qualidade de vida. Resultados: foram incluídos 10 artigos nesta revisão, que apresentaram dose mínima terapêutica, o impacto de injeções únicas e repetidas, seleção de músculos e pontos a serem aplicados. Conclusão: a TBA proporcionou uma melhora significativa sobre a espasticidade e funcionalidade da criança com PC espástica, em um período de até 3 meses após sua aplicação. Pode ser considerada uma opção de tratamento segura e eficaz, e a análise econômica da saúde demonstra que essa intervenção possui excelente relação custo-benefício.

For just over two decades, botulinum toxin type A (BoNT-A) has been used as part of a multimodal treatment to reduce muscle tone in children with spastic cerebral palsy (CP). Objectives: to determine the efficacy and safety, to evaluate the doses used in each age group and to compare the costs between the BoNT-A's for the treatment of spasticity in children with CP. Methods: a systematic review of studies published in the last 6 years, from 2017 to april 2022, was carried out through the PubMed, SciELO, Science Direct, Google Scholar and CAPES Periodicals databases, according to the following inclusion criteria: (1) search terms: botulinum toxin, spasticity and cerebral palsy; (2) language: portuguese, english and epanish; (3) design: trials randomized and double-blind clinical trials, systematic reviews and meta-analyses; (4) population: children and adolescents with spastic CP; (5) intervention: BoNT-A; (6) control group with other treatment for CP or without intervention; (7) outcome: change in Modified Ashworth Scale, adverse effects and quality of life. Results: 10 articles were included in this review, which presented the minimum therapeutic dose, the impact of single and repeated injections, selection of muscles and points to be applied. Conclusion: BoNT-A provided a significant improvement in spasticity and functionality in children with spastic CP, within a period of up to 3 months after its application. It can be considered a safe and effective treatment option, and the economic analysis of health demonstrates that this intervention has an excellent cost-benefit ratio.

The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study / A eficácia de propranolol, flunarizina, amitriptilina e toxina botulínica nas queixas e profilaxia da migrânea vestibular: um estudo controlado não randomizado

Abstract Introduction: Vestibular migraine is the most common cause of spontaneous episodic vertigo in adult patients and the second most common cause of vertigo in patients of all ages. Objective: To assess the effectiveness of oral medication type (propranolol, flunarizine, and amitriptyline) and botulinum toxin A application on vestibular symptoms, headache severity and attack frequency for vestibular migraine patients. Methods: Sixty patients with vestibular migraine were enrolled. Thirty patients received botulinum toxin A treatment (B+ group) in addition to the oral medication, whereas 30 patients received only oral medication (B− group). Headache severity was evaluated with Migraine Disability Assessment Scale and vertigo severity was evaluated with Dizziness Handicap Inventory scale. Vestibular migraine attack frequencies in the last three months were also evaluated. Results: There was a statistically significant decrement in mean Dizziness Handicap Inventory scores, Migraine Disability Assessment Scale scores and vertigo attack frequencies after treatment for all patients, B+ and B− group patients (p < 0.001 for all). The mean Migraine Disability Assessment Scale score gains (p < 0.001) and vertigo attack frequency gains (p = 0.003) were significantly higher in the B+ patients than B− patients. Conclusions: Both B+ and B− group patients exhibited significant improvement in vestibular migraine attack frequencies, Dizziness Handicap Inventory score and Migraine Disability Assessment Scale score values. However, botulinum toxin A application had a more pronounced effect for Migraine Disability Assessment Scale score gain and vestibular migraine attack frequency values, but not for Dizziness Handicap Inventory score gain values. Thus, botulinum toxin A application should be considered for vestibular migraine patients whose headache severity degrees are more profound. The oral medication type (propranolol, flunarizine or amitriptyline) did not differ in influencing the vestibular migraine attack frequency, Dizziness Handicap Inventory score gain and Migraine Disability Assessment Scale score gain values.

Resumo Introdução: A migrânea vestibular é a causa mais comum de vertigem episódica espontânea em pacientes adultos e a segunda causa mais comum de vertigem em pacientes de todas as idades. Objetivo: Avaliar a eficácia da aplicação dos tipos de medicamentos orais (propranolol, flunarizina e amitriptilina) e da toxina botulínica tipo A sobre os sintomas vestibulares, intensidade da cefaleia e frequência das crises em pacientes com migrânea vestibular. Método: Sessenta pacientes com migrânea vestibular foram incluídos. Trinta pacientes receberam tratamento com toxina botulínica tipo A e medicação oral (Grupo B+), enquanto 30 pacientes receberam apenas medicação oral (Grupo B-). A intensidade da cefaleia foi avaliada pelo migraine disability assessment scale e a gravidade da vertigem foi avaliada com o dizziness handicap inventory. A frequência das crises de migrânea vestibular nos últimos três meses também foi avaliada. Resultados: Houve um decréscimo estatisticamente significativo na média dos escores do dizziness handicap inventory e migraine disability assesment scale e na frequência das crises de vertigem após o tratamento em todos os pacientes, p < 0,001 para todos os pacientes dos grupos B+ e B−. Os ganhos médios no escore do migraine disability assesment scale (p < 0,001) e na frequência das crises de vertigem (p = 0,003) foram significantemente maiores nos pacientes B+ do que nos pacientes B−. Conclusões: Os pacientes de ambos os grupos B+ e B− exibiram melhoria significativa na frequência das crises de migrânea vestibular e nos valores dos escores do dizziness handicap inventory e do migraine disability assesment scale. No entanto, a aplicação da toxina botulínica tipo A teve um efeito mais pronunciado para os valores de ganho no escore do migraine disability assesment scale e na frequência das crises de migrânea vestibular, mas não para os valores de ganho no escore do dizziness handicap inventory. Portanto, a aplicação de toxina botulínica tipo A deve ser considerada para pacientes com migrânea vestibular, cujos graus de intensidade da cefaleia são mais marcantes. O tipo de medicação oral (propranolol, flunarizina ou amitriptilina) não diferiu em relação à frequência das crises de migrânea vestibular e aos valores de ganho dos escores do dizziness handicap inventory e do migraine disability assesment scale.

Comparative Study of 150 vs. 200 Units of Botulinum Toxin as Treatment for Vaginismus / Estudo comparativo de 150 vs. 200 unidades de toxina botulínica como tratamento para vaginismo

Abstract Objective To comparatively evaluate the outcome of treatment with 150 versus 200 units (U) of botulinum toxin in achieving pain-free intercourse and relieving muscle contraction in order to allow gynecological examination. Methods In this comparative prospective observational study, 99 patients with vaginismus were treated with botulinum toxin injections from September 2016 to August 2021. Diagnosis and grading of vaginismus severity were assessed using a Female Sexual Function Index (FSFI) questionnaire. Under local or general anesthesia, botulinum toxin diluted with preservative-free saline (150 U and 200 U) was injected into, above, and below the right and left bulbospongiosus muscle and the lateral submucosal areas of the introitus and perineal body using an insulin syringe. Patients were recalled after 2 weeks, and the postoperative outcome was recorded using a similar preoperative questionnaire. Results Overall, the mean age of patients was 30.2 years. The baseline and clinical characteristics were comparable between the 2 groups (p > 0.05). Significant improvements were seen in the pain and anxiety scores of finger penetration, dilator use, intercourse, and cotton swab in individual groups. The intergroup comparisons between 150 U and 200 U of Botox were not statistically significant (p > 0.05). Conclusion Low-dose Botox (150 U) is equally effective as high dose Botox injections (200 U) in vaginismus patients. Therefore, Botox-150 U can be used to treat vaginismus as an alternative to high doses of the same substance.

Resumo Objetivo Avaliar comparativamente o resultado do tratamento com 150 versus 200 unidades (U) de toxina botulínica na obtenção de relações sexuais sem dor e no alívio da contração muscular para permitir o exame ginecológico. Métodos Neste estudo observacional prospectivo comparativo, 99 pacientes com vaginismo foram tratadas com injeções de toxina botulínica de setembro de 2016 a agosto de 2021. O diagnóstico e a classificação da gravidade do vaginismo foram avaliados usando um questionário Female Sexual Function Index (FSFI). Sob anestesia local ou geral, injetou-se toxina botulínica diluída em soro fisiológico sem conservantes (150 U e 200 U) nos músculos bulbo esponjoso direito e esquerdo e nas áreas submucosas laterais do intróito e corpo perineal, utilizando-se uma seringa de insulina. Os pacientes foram chamados após 2 semanas, e o resultado pós-operatório foi registrado usando um questionário pré-operatório semelhante. Resultados No geral, a média de idade dos pacientes foi de 30,2 anos. As características basais e clínicas foram comparáveis entre os 2 grupos (p > 0,05). Melhorias significativas foram observadas nos escores de dor e ansiedade à penetração com dedo, uso de dilatador, relação sexual e cotonete em grupos individuais. As comparações intergrupos entre 150 U e 200 U Botox foram não estatisticamente significativas (p > 0,05). Conclusão Botox de baixa dose (150 U) é tão eficaz quanto injeções de Botox de alta dose (200 U) em pacientes com vaginismo. Portanto, o Botox-150 U pode ser usado para tratar o vaginismo como alternativa às altas doses da mesma substância.

The undesirable wink

Background: Marin-Amat syndrome is a rare acquired oculofacial synkinesis first reported in 1918. It manifests as involuntary eyelid closure on jaw opening or on lateral movement of the jaw following a peripheral facial nerve palsy. The increased orbicularis tone due to aberrant connections between the cranial nerve (CN) V and CN VII results in an undesirable wink with major psychosocial impact. Purpose: Most cases in literature were either observed or administered botulinum toxin injection to the orbicularis muscle. There are few sporadic reports of surgical interventions with successful outcomes.Hence there was a need to generate awareness regarding various modes of management of this rare entity. Synopsis: We present a video on the clinical presentation and management of six such patients, of whom one was bilateral. Five patients were females. Traumatic facial nerve paralysis and Bell’s palsy was previously diagnosed in one and five patients respectively. The mean age was 52 ± 9.48 years. The mean MRD (margin reflex distance) 1 and MRD 2 was 3.17 ± 0.60 and 5.33± 0.65 mm respectively. On smiling or on movement of the jaw the MRD 1 and 2 was reduced by 2. 50±0.40 and 1.50+/-0.40 mm respectively. Of the six patients four patients opted for nil intervention. Highlights: Botulinum toxin injection and preseptal orbicularis resection in the upper and lower eyelid along with blepharoplasty was performed in 1 patient each. Satisfactory reduction in the synkinetic movement was achieved in both. Marin-Amat syndrome is a rare often underdiagnosed synkinetic disorder following peripheral facial nerve palsy. Botulinum toxin injection and preseptal orbicularis resection are viable management options

Clinical trial combining botulinum toxin A injection and fissurectomy for chronic anal fissure: a dose-dependent study

ABSTRACT Background Anal fissure is a common surgical disease that is usually treated conservatively. The golden surgical treatment for anal fissure is lateral internal sphincterotomy, but it may result in multiple complications. Therefore, other treatment methods have recently been introduced, and one of them is the injection of botulinum toxin A (BTA) and fissurectomy. In the present study, we aim to evaluate the effectiveness of the combination of fissurectomy and BTA injection in the treatment of chronic anal fissure by single surgeon. Materials and Methods The present is a non-randomized prospective cohort study conducted by a single surgeon in Saudi Arabia. Our sample was composed of 116 female patients, with mean age of 36.57 ± 11.52 years, who presented to our Surgical Outpatient Clinic with chronic anal fissure between October 2015 and July 2020, and were treated with BTA injection combined with fissurectomy. They were followed up for 1, 2, 3, 4, and 8 weeks, and after one year to evaluate the efficacy and safety of the treatment. The main outcomes analyzed were symptomatic relief, complications, recurrence, and the need for further surgical intervention. Results The treatment with BTA injection combined with fissurectomy was effective and safe in 115 patients (99.1%) at 1 year of follow-up. A total of 5 patients experienced recurrence at 8 weeks, which resolved completely with pharmacological sphincterotomy, and 12 patients experienced minor incontinence, which disappeared later. Conclusion In total, 70 units of BTA injection combined with fissurectomy is a suitable second-line treatment of choice for chronic anal fissure, with a high degree of success and a low rate of major morbidity. (AU)